Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTFAV
- Development stage
- Unknown
- Lead developer
- Favnox Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
GTFAV is an injectable antioxidant combination product developed by Favnox Pharmaceuticals, containing 600mg of glutathione and ascorbic acid (vitamin C). It is designed for intravenous administration to provide cellular protection against oxidative stress. The combination utilizes the synergistic relationship between glutathione, a key intracellular antioxidant, and ascorbic acid, which acts as a reducing agent to maintain glutathione in its active form. It is primarily used for antioxidant support and various off-label clinical applications.
- Brand names
- GTFAV
- Other names
- Glutathione + Vit C 600mgglutathione + ascorbic acid
02
Targets
GSH (Glutathione)
Beyond the preview
Go deeper on GTFAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTFAV.